VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
AstraZeneca PLC vs Marsh & McLennan Companies, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisMarsh & McLennan Companies, Inc.
MMC · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Marsh & McLennan Companies, Inc.'s moat claims, evidence, and risks.
View MMC analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 65 / 100 for Marsh & McLennan Companies, Inc.).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Marsh & McLennan Companies, Inc. has 2 segments (62.8% in Risk and Insurance Services).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Marsh & McLennan Companies, Inc. has 5 across 3.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Marsh & McLennan Companies, Inc.
Risk and Insurance Services
Insurance brokerage, risk advisory, and reinsurance brokerage/services
Global
Enterprises, public entities, associations, and individuals (via broker/agent channels)
Intermediary + advisor (insurance/reinsurance market intermediary)
62.8%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
Marsh & McLennan Companies, Inc. strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Marsh & McLennan Companies, Inc. segments
Full profile >Risk and Insurance Services
Oligopoly
Consulting
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.